Clinical Trial Update: Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. [Phase 4]

View source ↗

Summary

A decentralized N=1 trial evaluates individual response to dapagliflozin in type 2 diabetes patients, completed phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Albuminuria
• Chronic Kidney Disease
• Chronic Kidney Disease Due to Type Diabetes Mellitus
• Diabetes Complications
• Diabetes with Proteinuria
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | Phase 4 | Status: COMPLETED